Rigel Pharmaceuticals reports Q1 2026 revenue of $58.8M and $8.7M net income, advancing clinical trials.

Rigel Pharmaceuticals announced $58.8 million in total revenues and $8.7 million net income for Q1 2026, driven by a 26% increase in net product sales. The company is progressing its Phase 1b study of R289, targeting lower-risk myelodysplastic syndrome, with dose expansion enrollment expected to complete in H2 2026. Rigel reaffirmed its 2026 revenue guidance of $275-$290 million and anticipates positive net income for the full year while continuing clinical development and business growth.